Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic ß-cells.

Introduction: In a recent study, we confirmed good chemical and physical compatibility of microencapsulated pancreatic β-cells using a novel formulation of low viscosity sodium alginate (LVSA), Poly-L-Ornithine (PLO), and the tertiary bile acid, ursodeoxycholic acid (UDCA). This study aimed to inves...

Full description

Bibliographic Details
Main Authors: Mooranian, Armin, Negrulj, R., Arfuso, Frank, Al-Salami, Hani
Format: Journal Article
Published: 2014
Online Access:http://hdl.handle.net/20.500.11937/8432
_version_ 1848745657016254464
author Mooranian, Armin
Negrulj, R.
Arfuso, Frank
Al-Salami, Hani
author_facet Mooranian, Armin
Negrulj, R.
Arfuso, Frank
Al-Salami, Hani
author_sort Mooranian, Armin
building Curtin Institutional Repository
collection Online Access
description Introduction: In a recent study, we confirmed good chemical and physical compatibility of microencapsulated pancreatic β-cells using a novel formulation of low viscosity sodium alginate (LVSA), Poly-L-Ornithine (PLO), and the tertiary bile acid, ursodeoxycholic acid (UDCA). This study aimed to investigate the effect of UDCA on the morphology, swelling, stability, and size of these new microcapsules. It also aimed to evaluate cell viability in the microcapsules following UDCA addition. Materials and methods: Microencapsulation was carried out using a Büchi-based system. Two (LVSA-PLO, control and LVSA-PLO-UDCA, test) pancreatic β-cells microcapsules were prepared at a constant ratio of 10:1:3, respectively. The microcapsules’ morphology, cell viability, swelling characteristics, stability, mechanical strength, Zeta potential, and size analysis were examined. The cell contents in each microcapsule and the microencapsulation efficiency were also examined. Results: The addition of UDCA did not affect the microcapsules’ morphology, stability, size, or the microencapsulation efficiency. However, UDCA enhanced cell viability in the microcapsules 24 h after microencapsulation (p < 0.01), reduced swelling (p < 0.05), reduced Zeta potential (− 73 ± 2 to − 54 ± 2 mV, p < 0.01), and increased mechanical strength of the microcapsules (p < 0.05) at the end of the 24-h experimental period. Discussion and conclusion: UDCA increased β-cell viability in the microcapsules without affecting the microcapsules’ size, morphology, or stability. It also increased the microcapsules’ resistance to swelling and optimized their mechanical strength. Our findings suggest potential benefits of the bile acid UDCA in β-cell microencapsulation.
first_indexed 2025-11-14T06:20:50Z
format Journal Article
id curtin-20.500.11937-8432
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T06:20:50Z
publishDate 2014
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-84322017-09-13T14:38:33Z Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic ß-cells. Mooranian, Armin Negrulj, R. Arfuso, Frank Al-Salami, Hani Introduction: In a recent study, we confirmed good chemical and physical compatibility of microencapsulated pancreatic β-cells using a novel formulation of low viscosity sodium alginate (LVSA), Poly-L-Ornithine (PLO), and the tertiary bile acid, ursodeoxycholic acid (UDCA). This study aimed to investigate the effect of UDCA on the morphology, swelling, stability, and size of these new microcapsules. It also aimed to evaluate cell viability in the microcapsules following UDCA addition. Materials and methods: Microencapsulation was carried out using a Büchi-based system. Two (LVSA-PLO, control and LVSA-PLO-UDCA, test) pancreatic β-cells microcapsules were prepared at a constant ratio of 10:1:3, respectively. The microcapsules’ morphology, cell viability, swelling characteristics, stability, mechanical strength, Zeta potential, and size analysis were examined. The cell contents in each microcapsule and the microencapsulation efficiency were also examined. Results: The addition of UDCA did not affect the microcapsules’ morphology, stability, size, or the microencapsulation efficiency. However, UDCA enhanced cell viability in the microcapsules 24 h after microencapsulation (p < 0.01), reduced swelling (p < 0.05), reduced Zeta potential (− 73 ± 2 to − 54 ± 2 mV, p < 0.01), and increased mechanical strength of the microcapsules (p < 0.05) at the end of the 24-h experimental period. Discussion and conclusion: UDCA increased β-cell viability in the microcapsules without affecting the microcapsules’ size, morphology, or stability. It also increased the microcapsules’ resistance to swelling and optimized their mechanical strength. Our findings suggest potential benefits of the bile acid UDCA in β-cell microencapsulation. 2014 Journal Article http://hdl.handle.net/20.500.11937/8432 10.3109/21691401.2014.934457 restricted
spellingShingle Mooranian, Armin
Negrulj, R.
Arfuso, Frank
Al-Salami, Hani
Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic ß-cells.
title Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic ß-cells.
title_full Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic ß-cells.
title_fullStr Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic ß-cells.
title_full_unstemmed Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic ß-cells.
title_short Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic ß-cells.
title_sort characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic ß-cells.
url http://hdl.handle.net/20.500.11937/8432